Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics

Abstract

Aim

Nano drug delivery systems can provide the opportunity to reduce side effects and improve the therapeutic aspect of a variety of drugs. Bortezomib (BTZ) is a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. Severe side effects of BTZ are the major dose-limiting factor. Particulate drug delivery systems for BTZ are polymeric and lipidic drug delivery systems. This review focussed on lipidic-nano drug delivery systems (LNDDSs) for the delivery of BTZ.

Results

LNDDSs including liposomes, solid lipid nanoparticles, and self-nanoemulsifying drug delivery systems showed reduce systemic side effects, improved therapeutic efficacy, and increased intestinal absorption. Besides LNDDSs were used to target-delivery of BTZ to cancer.

Conclusion

Overall, LNDDSs can be considered as a novel delivery system for BTZ to resolve the treatment-associated restrictions.

Keywords:

• Bortezomib
• liposomes
• solid lipid nanoparticles
• self-nanoemulsifying drug delivery systems
• formulation
• pharmacokinetics

Disclosure statement

No potential conflict of interest was reported by the author(s).